Common questions about IKERVIS (FAQ)
Q: How quickly does IKERVIS typically start working to relieve symptoms?
A: IKERVIS is a type of medicine called an immunomodulator, which means it works by gradually modifying the underlying inflammatory response. According to official product information, the full therapeutic effect develops over time. Clinical studies generally evaluated the condition’s response over a period of six months or more.
Q: Can I use IKERVIS with other over-the-counter artificial tears?
A: Yes, IKERVIS can be used alongside other topical ophthalmic medicines, which includes artificial tears. Regulatory documents require that all other eye drops be administered at least 15 minutes before applying IKERVIS. Official guidance requires that IKERVIS be the final medicine instilled in any co-administration regimen.
Q: Does IKERVIS interact with common medications like blood pressure pills or NSAIDs?
A: Official product information notes that because IKERVIS is applied topically to the eye, only a minimal amount of the active ingredient, cyclosporine, is absorbed into the bloodstream. Due to this minimal systemic exposure, regulatory documents indicate no systemic interactions have been established or formally studied with oral medications.
Q: Do I need to wait a certain time before using other eye drops after IKERVIS?
A: When co-administering multiple eye drops, official guidance specifies that IKERVIS must be the final drop instilled in any co-administration regimen. A minimum of 15 minutes is still required to separate all applications.
Q: Is IKERVIS supposed to reduce the redness in my eyes?
A: IKERVIS is intended to reduce the underlying inflammation associated with severe dry eye disease. While this may lead to an improvement in symptoms, it is noted that ocular hyperaemia (eye redness) is also a common, temporary side effect that can occur after instillation, according to official safety information.
Q: What does the research say about stopping IKERVIS and the return of symptoms?
A: IKERVIS is indicated for the long-term management of chronic inflammation. Official documents suggest that if treatment is discontinued, the specific corneal inflammation may no longer be controlled. If discontinuing IKERVIS, it is important to follow the guidance of the prescribing specialist regarding monitoring and follow-up.
Q: What does IKERVIS feel like when you put it in?
A: It is common to experience some local sensations when using IKERVIS. According to regulatory documentation, eye pain and eye irritation are very common side effects reported during the instillation process. These sensations are commonly reported as transitory and typically lessen shortly after application.
Q: Why does IKERVIS come in single-use vials?
A: IKERVIS is provided in single-dose containers as a sterile, preservative-free emulsion. This packaging helps maintain the product's sterility, as each vial is designed for a single use only. Any remaining medicine must be discarded immediately after use.
Q: How long can a single vial of IKERVIS be kept after opening?
A: The single-dose container of IKERVIS is intended for one application only. For safety and sterility, all regulatory instructions state that any unused emulsion remaining in the vial must be discarded immediately after you have used the drops, and it should not be saved or reused for a later application.
Q: What happens if I accidentally put too many IKERVIS drops in my eye?
A: According to official safety information, a topical overdose is not likely to occur after using the drops on the eye. If you accidentally use more than one drop, it is generally advised to rinse the eye with water. If there is any concern about overdose, consulting a healthcare professional is recommended.
Q: Are there any cosmetic side effects like changes in eyelash growth?
A: Official safety documents include a comprehensive list of all observed adverse events in clinical trials. The list of adverse events reported in official product information does not include changes in eyelash growth as a side effect for IKERVIS.
Q: How does the active ingredient in IKERVIS specifically target dry eye?
A: The active ingredient, ciclosporin, is a topical immunomodulator. It works by suppressing the activity of immune cells called T-lymphocytes on the eye's surface. This suppression is part of the drug’s intended action to manage the chronic inflammation associated with severe keratitis in dry eye disease.
Q: What research or clinical trials support the use of IKERVIS?
A: The benefits and safety of IKERVIS were assessed through several clinical trials reviewed by regulatory bodies. The main study used to support its approval involved 246 patients with severe dry eye disease, where it was compared with the vehicle (the drops without the active medicine) over a six-month period.
Q: Does IKERVIS have any known interactions with alcohol or caffeine?
A: Due to the minimal systemic absorption of IKERVIS, no formal studies were conducted on systemic interactions with food, alcohol, or herbal products. Therefore, there are no established regulatory statements concerning these specific interactions.
Q: Is it normal for my vision to be slightly cloudy right after putting in the drops?
A: Blurred vision is listed as a Common side effect in regulatory documents that occurs immediately after the eye drops are used. This effect is short-lasting, and you should wait until your vision clears before engaging in activities like driving or operating machinery.
Q: Do I need to tell my dentist I am using IKERVIS?
A: General guidance from regulatory sources suggests informing any healthcare professional who treats you, including doctors, dentists, or pharmacists, about all medicines you are taking. This ensures they have full visibility into your current medications.
Q: Is the vehicle/carrier solution in IKERVIS different from other eye drops?
A: Yes, IKERVIS utilizes a specific formulation known as a cationic nanoemulsion. This advanced technology is designed to enhance the retention of the medication on the surface of the eye, which helps support its convenient, once-daily application.
